New registry aims to uncover risks of YORVIPATH during pregnancy
NCT ID NCT07345494
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry study is collecting data from 50 women aged 15–50 who took YORVIPATH (palopegteriparatide) for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will monitor pregnancy complications, birth outcomes, and infant health through the first year of life. The goal is to better understand any risks to the mother, fetus, or baby from this medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palopegteriparatide (YORVIPATH)
What this could lead to
If successful, this registry could provide crucial safety data on using YORVIPATH during pregnancy and breastfeeding, helping doctors and patients make informed treatment decisions.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. The small size (50 participants) and lack of a comparison group limit the strength of conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGMorgantown, West Virginia, 26508, United States